Time for a change: addressing R&D and commercialization challenges for antibacterials - Wikidata - wikimedia - TriplyDB

Time for a change: addressing R&D and commercialization challenges for antibacterials

Time for a change: addressing R&D and commercialization challenges for antibacterials

http://www.wikidata.org/entity/Q28085068

about

An open source pharma roadmap Thiophene antibacterials that allosterically stabilize DNA-cleavage complexes with DNA gyrase Characterization and prediction of the mechanism of action of antibiotics through NMR metabolomics.Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.Broad-range lytic bacteriophages that kill Staphylococcus aureus local field strains.The antibiotic pipeline: reviving research and development and speeding drugs to market.Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening.Within-host dynamics of infection: from ecological insights to evolutionary predictions.Antimicrobial resistance: addressing the threat to global health. Preface Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens.A new class of antibacterials, the imidazopyrazinones, reveal structural transitions involved in DNA gyrase poisoning and mechanisms of resistance.The Macromolecular Machines that Duplicate the Escherichia coli Chromosome as Targets for Drug Discovery.Macroscopic electric field inside water-filled biological nanopores.Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top.Antibiotic resistance: a rundown of a global crisis Electronic laboratory notebooks in a public–private partnership

P2860

Q29475096-7DC2C061-8BA0-4E2A-B7A4-D3E57DA5A818 Q33782498-30522809-D14F-485F-91B4-04F4F33F2C2F Q36012460-4E8E7A15-70C0-4BEE-AE03-57BA977BE760 Q38793981-1232F308-6DDA-4904-9F67-AB9E21A97309 Q40120490-E3CABD0E-2596-4DC9-A0E9-571B331748C5 Q40290086-808281F5-3C61-4F60-BFFD-4EE80CD2AA16 Q41077819-3B6724E6-389F-47CF-96E2-580DF6F9E559 Q42425875-3544914E-4463-45DD-809C-8DF7A49D3A99 Q42564133-EB1E3283-EF55-4E1B-8488-9A466ABD0858 Q50069002-30A28FDF-B373-478B-B6B6-5494379B77B1 Q52355825-DADF7CC0-1CBF-46B8-8E59-4ABE31AD6BCA Q52656083-64A0BABA-F595-4C39-B2DC-9D0A6A45B639 Q53794879-3506E2B0-B7C6-4FA1-8534-28FCC2ED0DE4 Q55340953-8D170491-3D90-4A8F-A681-BE3EE99E1B4E Q57816209-AA6F9940-2B12-4722-977A-6ED53F791B85 Q57816701-BCF16483-C650-4B26-8B2C-9EADF4E43845

P2860

Time for a change: addressing R&D and commercialization challenges for antibacterials

http://www.wikidata.org/entity/Q28085068

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Time for a change: addressing R&D and commercialization challenges for antibacterials

@ast

Time for a change: addressing R&D and commercialization challenges for antibacterials

@en

Time for a change: addressing R&D and commercialization challenges for antibacterials

@nl

type

label

Time for a change: addressing R&D and commercialization challenges for antibacterials

@ast

Time for a change: addressing R&D and commercialization challenges for antibacterials

@en

Time for a change: addressing R&D and commercialization challenges for antibacterials

@nl

prefLabel

Time for a change: addressing R&D and commercialization challenges for antibacterials

@ast

Time for a change: addressing R&D and commercialization challenges for antibacterials

@en

Time for a change: addressing R&D and commercialization challenges for antibacterials

@nl

P1433

Q28085068-6B1E8D62-AF3C-4F09-BD30-12E1A7251114

P1476

Q28085068-96B2AE32-4B0A-4047-97F5-7698E4AB55CA

P2093

Q28085068-5C30D414-7A98-4E9E-A022-F0B1D3D98177

Q28085068-8AA55924-0D89-4CFA-8FA2-17CD78C70921

Q28085068-8ED1B58F-6B04-4651-B98D-2D8261BD4F1C

Q28085068-A10D0FF5-552C-4445-9216-0689BB1E0406

Q28085068-A1FFB61F-048A-4E78-946C-C25BD7AE5D49

P2860

Q28085068-02A864C6-4030-4542-A721-B4985173C18E

Q28085068-05B08391-7D72-4FD7-AA32-C04D1AE3D150

Q28085068-14F903E2-714D-47CE-B3D1-5AF34B1E03C6

Q28085068-2F2770E8-2FF2-407E-A9EC-53A33C5D438C

Q28085068-3667F891-D1E6-4B47-88EB-886DFB1F92B2

Q28085068-50D6A74D-F289-4891-9CB8-7357AF5FFEC8

Q28085068-63C1566D-27B9-4D68-92E9-896499A57C00

Q28085068-7CA2E373-ACBF-4754-8085-79CB4EF8D001

Q28085068-9B1F0596-D1E1-4C0D-BF13-5590F4534144

Q28085068-9F1D716A-B03F-457A-BC21-66364A0A1589

P304

Q28085068-CC95DB9D-AB6B-401F-BAF5-01156CDBF5D9

P31

Q28085068-94FB0E16-6576-49FA-A95C-BECE345B9242

P3181

Q28085068-B96468F6-02A8-4EA8-9AA7-BA935BCB3E98

P356

Q28085068-8B774A16-F99A-4384-902E-1168D8D2A7F5

P407

Q28085068-D4898122-9F04-47A2-BD94-910AA4A745C2

P433

Q28085068-73DE8C67-4973-44D3-B708-BA1C1C3CC14F

P478

Q28085068-DEE67A3F-AEBB-4E2E-AA09-09F0458CC4A9

P577

Q28085068-A3ED3B71-6C98-4B21-8878-4A2FD0B4C504

P5875

Q28085068-8A78D4D9-080E-4448-8186-1F55FD771783

P698

Q28085068-A2D9F4CD-2009-422D-BEC7-CBD623B7B904

P921

Q28085068-06A02F2C-C9C1-4A36-A8C5-12292DB2DB11

P932

Q28085068-CEE5871D-2CC8-4780-8BFD-6DC290590C2C

P3181

P356

P1433

Philosophical Transactions of the Royal Society B

P1476

Time for a change: addressing R&D and commercialization challenges for antibacterials

@en

P2093

D. Findlay

http://www.w3.org/2001/XMLSchema#string

D. J. Payne

http://www.w3.org/2001/XMLSchema#string

J. Anderson

http://www.w3.org/2001/XMLSchema#string

L. F. Miller

http://www.w3.org/2001/XMLSchema#string

L. Marks

http://www.w3.org/2001/XMLSchema#string

P2860

Type IIA topoisomerase inhibition by a new class of antibacterial agents

How to improve R&D productivity: the pharmaceutical industry's grand challenge

Host response to respiratory bacterial pathogens as identified by integrated analysis of human gene expression data

Drugs for bad bugs: confronting the challenges of antibacterial discovery

Cancer immunotherapy comes of age

Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.

Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.

Improvement of the pharmacokinetics and in vivo antibacterial efficacy of a novel type IIa topoisomerase inhibitor by formulation in liposomes.

Better tests, better care: improved diagnostics for infectious diseases.

Clostridium difficile infection in the twenty-first century.

P304

20140086

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1765545

http://www.w3.org/2001/XMLSchema#string

P356

10.1098/RSTB.2014.0086

http://www.w3.org/2001/XMLSchema#string

P407

P433

1670

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275586317

http://www.w3.org/2001/XMLSchema#string

P698

25918443

http://www.w3.org/2001/XMLSchema#string

P921

commercialization

P932

4424435

http://www.w3.org/2001/XMLSchema#string